After teasing a new regulatory…
After teasing a new regulatory process for personalized genetic medicines [...]
Rome-based Angelini Pharma has…
Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts [...]
A phase 3 study of Gossamer…
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary [...]
Ionis Pharmaceuticals has pulled…
Ionis Pharmaceuticals has pulled the plug on an early investigational [...]
After an FDA rejection of its…
After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven [...]
Four years after he resigned as…
Four years after he resigned as chief medical officer at [...]
As Candel Therapeutics gears up…
As Candel Therapeutics gears up for a planned U.S. approval [...]
The Swiss drugmaker has plucked an…
The Swiss drugmaker has plucked an experienced scientist from Down [...]
Novartis has jettisoned an…
Novartis has jettisoned an anti-cancer protein from its pipeline after [...]
Politico has reported that the…
Politico has reported that the White House isn’t happy with [...]